Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone510-970-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$84.45 million
Profitability
Miscellaneous
Employees302
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions
What is Sangamo Therapeutics' stock symbol?
Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."
How were Sangamo Therapeutics' earnings last quarter?
Sangamo Therapeutics Inc (NASDAQ:SGMO) released its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.09. The biopharmaceutical company had revenue of $17.55 million for the quarter, compared to analyst estimates of $13.58 million. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 27.32%. Sangamo Therapeutics's quarterly revenue was down 18.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.17) earnings per share. View Sangamo Therapeutics' Earnings History.
When is Sangamo Therapeutics' next earnings date?
What price target have analysts set for SGMO?
4 Wall Street analysts have issued twelve-month target prices for Sangamo Therapeutics' shares. Their forecasts range from $11.00 to $18.00. On average, they anticipate Sangamo Therapeutics' stock price to reach $14.00 in the next year. This suggests a possible upside of 74.3% from the stock's current price. View Analyst Price Targets for Sangamo Therapeutics.
What is the consensus analysts' recommendation for Sangamo Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sangamo Therapeutics.
Has Sangamo Therapeutics been receiving favorable news coverage?
Press coverage about SGMO stock has been trending negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sangamo Therapeutics earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Sangamo Therapeutics.
Who are some of Sangamo Therapeutics' key competitors?
Some companies that are related to Sangamo Therapeutics include Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Alector (ALEC) and Editas Medicine (EDIT).
What other stocks do shareholders of Sangamo Therapeutics own?
Who are Sangamo Therapeutics' key executives?
Sangamo Therapeutics' management team includes the folowing people:
- Dr. Alexander D. Macrae, CEO, Pres & Director (Age 56)
- Ms. Kathy Y. Yi, EVP, CFO, Principal Accounting Officer & Sec. (Age 47)
- Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 46)
- Dr. Edward Rebar, Sr. VP & CTO
- Mr. McDavid Stilwell, VP of Corp. Communications & Investor Relations
How do I buy shares of Sangamo Therapeutics?
Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sangamo Therapeutics' stock price today?
One share of SGMO stock can currently be purchased for approximately $8.03.
How big of a company is Sangamo Therapeutics?
Sangamo Therapeutics has a market capitalization of $928.91 million and generates $84.45 million in revenue each year. The biopharmaceutical company earns $-68,330,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.View Additional Information About Sangamo Therapeutics.
What is Sangamo Therapeutics' official website?
How can I contact Sangamo Therapeutics?
Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]
MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
